作者:Kei Kitamura、Naoyuki Shimada、Craig Stewart、Abdurrahman C. Atesin、Tülay A. Ateşin、Marcus A. Tius
DOI:10.1002/anie.201500881
日期:2015.5.18
A Pd0‐catalyzed asymmetric Nazarov‐type cyclization is described. The optimized ligand for the reaction incorporates a weakly coordinating pyridine ring into a TADDOL‐derived phosphoramidite (TADDOL=α,α,α,α‐tetraaryl‐1,3‐dioxolane‐4,5‐dimethanol). The reaction leads to the formation of cyclopentenones as single diastereoisomers that incorporate two contiguous asymmetric centers, one tertiary and one
作者:Anais Jolit、Cody F. Dickinson、Kei Kitamura、Patrick M. Walleser、Glenn P. A. Yap、Marcus A. Tius
DOI:10.1002/ejoc.201701117
日期:2017.11.2
The detailed account of an asymmetric Nazarovcyclization that leads to α-hydroxycyclopentenones bearing either vicinal, all-carbon atom quaternary centers, or vicinalquaternary and tertiary centers is described. The all-aliphatic examples represent the greatest challenge as the dienone starting materials are not activated toward cyclization by an aryl group. The rational design and optimization of
Rhodium/bisphosphine-thiourea-catalyzed enantioselective hydrogenation of α,β-unsaturated N-acylpyrazoles
作者:Pan Li、Xinquan Hu、Xiu-Qin Dong、Xumu Zhang
DOI:10.1039/c6cc04987g
日期:——
We successfully extended our Rh/bisphosphine-thiourea (ZhaoPhos) catalytic system to asymmetric hydrogenation of α,β-unsaturated N-acylpyrazoles affording products with high yields and excellent enantioselectivities (up to 97% yield, 99% ee).
[EN] A STEREOISOMERICALLY PURE NK-3 RECEPTOR ANTAGONIST AND CRYSTALLINE FORMS THEREOF<br/>[FR] ANTAGONISTE DU RÉCEPTEUR DE TYPE NK-3 STÉRÉOISOMÉRIQUEMENT PUR ET FORMES CRISTALLINES DE CELUI-CI
申请人:MILLENDO THERAPEUTICS INC
公开号:WO2021030335A1
公开(公告)日:2021-02-18
A stereoisomerically pure NK-3 receptor antagonist is provided, including crystalline free base and salt forms thereof, as well as pharmaceutical compositions comprising the same. Also provided are methods for production of the stereoisomerically pure NK-3 receptor antagonist, as well as its use in the context of treating conditions for which antagonism of the NK-3 receptor is desired.